RAI Use in Intermediate-Risk Thyroid Cancer

This session will provide a comprehensive overview of the major guideline changes in differentiated thyroid cancer and implications for clinical practice. Key topics include revised risk stratification criteria, updated surgical recommendations, refined guidelines for radioactive iodine therapy, role of molecular markers, and new strategies for surveillance and long-term followup

Chair

Lindsay Ann Bischoff, MD

Vanderbilt University Medical Center Endocrine

RAI Use in Intermediate-Risk Thyroid Cancer

Trevor E Angell, MD

Keck Medicine of USC

Surgical Updates to Thyroid Cancer Management

Julie Ann Sosa, MD

UCSF

Chair

Stephanie Anne Fish, MD

Memorial Sloan-Kettering Cancer Center